|
1
|
Yamaguchi R, Lartigue L and Perkins G:
Targeting Mcl-1 and other Bcl-2 family member proteins in cancer
therapy. Pharmacol Ther. 195:13–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Juin P, Geneste O, Gautier F, Depil S and
Campone M: Decoding and unlocking the BCL-2 dependency of cancer
cells. Nat Rev Cancer. 13:455–465. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adams CM, Clark-Garvey S, Porcu P and
Eischen CM: Targeting the Bcl-2 family in B cell lymphoma. Front
Oncol. 8:6362019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bhola PD and Letai A: Mitochondria-judges
and executioners of cell death sentences. Mol Cell. 61:695–704.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ow TJ, Fulcher CD, Thomas C, Broin PO,
López A, Reyna DE, Smith RV, Sarta C, Prystowsky MB, Schlecht NF,
et al: Optimal targeting of BCL-family proteins in head and neck
squamous cell carcinoma requires inhibition of both BCL-xL and
MCL-1. Oncotarget. 10:494–510. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gores GJ and Kaufmann SH: Selectively
targeting Mcl-1 for the treatment of acute myelogenous leukemia and
solid tumors. Genes Dev. 26:305–311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Glaser SP, Lee EF, Trounson E, Bouillet P,
Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, et
al: Anti-apoptotic Mcl-1 is essential for the development and
sustained growth of acute myeloid leukemia. Genes Dev. 26:120–125.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tutusaus A, Stefanovic M, Boix L, Cucarull
B, Zamora A, Blasco L, de Frutos PG, Reig M, Fernandez-Checa JC,
Marí M, et al: Antiapoptotic BCL-2 proteins determine
sorafenib/regorafenib resistance and BH3-mimetic efficacy in
hepatocellular carcinoma. Oncotarget. 9:16701–16717. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Souers AJ, Leverson JD, Boghaert ER,
Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH,
Fairbrother WJ, et al: ABT-199, a potent and selective BCL-2
inhibitor, achieves antitumor activity while sparing platelets. Nat
Med. 19:202–208. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gupta VA, Matulis SM, Conage-Pough JE,
Nooka AK, Kaufman JL, Lonial S and Boise LH: Bone marrow
microenvironment-derived signals induce Mcl-1 dependence in
multiple myeloma. Blood. 129:1969–1979. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Konopleva M, Milella M, Ruvolo P, Watts
JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo
P, et al: MEK inhibition enhances ABT-737-induced leukemia cell
apoptosis via prevention of ERK-activated MCL-1 induction and
modulation of MCL-1/BIM complex. Leukemia. 26:778–787. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Beroukhim R, Mermel CH, Porter D, Wei G,
Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J,
Urashima M, et al: The landscape of somatic copy-number alteration
across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang H, Guttikonda S, Roberts L, Uziel T,
Semizarov D, Elmore SW, Leverson JD and Lam LT: Mcl-1 is critical
for survival in a subgroup of non-small-cell lung cancer cell
lines. Oncogene. 30:1963–1968. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kelly GL, Grabow S, Glaser SP, Fitzsimmons
L, Aubrey BJ, Okamoto T, Valente LJ, Robati M, Tai L, Fairlie WD,
et al: Targeting of MCL-1 kills MYC-driven mouse and human
lymphomas even when they bear mutations in p53. Genes Dev.
28:58–70. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bate-Eya LT, den Hartog IJ, van der Ploeg
I, Schild L, Koster J, Santo EE, Westerhout EM, Versteeg R, Caron
HN, Molenaar JJ and Dolman ME: High efficacy of the BCL-2 inhibitor
ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell
lines and xenografts and rational for combination with MCL-1
inhibition. Oncotarget. 7:27946–27958. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin J, Fu D, Dai Y, Lin J and Xu T: Mcl-1
inhibitor suppresses tumor growth of esophageal squamous cell
carcinoma in a mouse model. Oncotarget. 8:114457–114462.
2017.PubMed/NCBI
|
|
19
|
Wertz IE, Kusam S, Lam C, Okamoto T,
Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al:
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1
and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akagi H, Higuchi H, Sumimoto H, Igarashi
T, Kabashima A, Mizuguchi H, Izumiya M, Sakai G, Adachi M,
Funakoshi S, et al: Suppression of myeloid cell leukemia-1 (Mcl-1)
enhances chemotherapy-associated apoptosis in gastric cancer cells.
Gastric Cancer. 16:100–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yecies D, Carlson NE, Deng J and Letai A:
Acquired resistance to ABT-737 in lymphoma cells that up-regulate
MCL-1 and BFL-1. Blood. 115:3304–3313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song L, Coppola D, Livingston S, Cress D
and Haura EB: Mcl-1 regulatessurvival and sensitivity to diverse
apoptotic stimuli inhuman non-small cell lung cancer cells. Cancer
Biol Ther. 4:267–276. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xiang W, Yang CY and Bai L: MCL-1
inhibition in cancer treatment. Onco Targets Ther. 11:7301–7314.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H,
Dong XW, Hu YZ, Lin NM, He QJ and Yang B: Synergistic antitumor
activity of gemcitabine and ABT-737 in vitro and in vivo through
disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther.
10:1264–1275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stewart ML, Fire E, Keating AE and
Walensky LD: The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor
and apoptosis sensitizer. Nat Chem Biol. 6:595–601. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Placzek WJ, Sturlese M, Wu B, Cellitti JF,
Wei J and Pellecchia M: Identification of a novel Mcl-1 protein
binding motif. J Biol Chem. 286:39829–39835. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Muppidi A, Doi K, Edwardraja S, Drake EJ,
Gulick AM, Wang HG and Lin Q: Rational design of proteolytically
stable, cell-permeable peptide-based selective Mcl-1 inhibitors. J
Am Chem Soc. 134:14734–14737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan R, Ruvolo VR, Wei J, Konopleva M, Reed
JC, Pellecchia M, Andreeff M and Ruvolo PP: Inhibition of Mcl-1
with the pan-Bcl-2 family inhibitor (−)BI97D6 overcomes ABT-737
resistance in acute myeloid leukemia. Blood. 126:363–372. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rheinländer A, Schraven B and Bommhardt U:
CD45 in human physiology and clinical medicine. Immunol Lett.
196:22–32. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Foight GW, Ryan JA, Gulla SV, Letai A and
Keating AE: Designed BH3 peptides with high affinity and
specificity for targeting Mcl-1 in cells. ACS Chem Biol.
9:1962–1968. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vo TT, Ryan J, Carrasco R, Neuberg D,
Rossi DJ, Stone RM, Deangelo DJ, Frattini MG and Letai A: Relative
mitochondrial priming of myeloblasts and normal HSCs determines
chemotherapeutic success in AML. Cell. 151:344–355. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jilg S, Reidel V, Muller-Thomas C, Konig
J, Schauwecker J, Hockendorf U, Huberle C, Gorka O, Schmidt B,
Burgkart R, et al: Blockade of BCL-2 proteins efficiently induces
apoptosis in progenitor cells of high-risk myelodysplastic
syndromes patients. Leukemia. 30:112–123. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tao ZF, Hasvold L, Wang L, Wang X, Petros
AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM, et al:
Discovery of a potent and selective BCL-XL inhibitor with in vivo
activity. ACS Med Chem Lett. 5:1088–1093. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bernardo PH, Sivaraman T, Wan KF, Xu J,
Krishnamoorthy J, Song CM, Tian L, Chin JS, Lim DS, Mok HY, et al:
Structural insights into the design of small molecule inhibitors
that selectively antagonize Mcl-1. J Med Chem. 53:2314–2318. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiao Y, Nimmer P, Sheppard GS, Bruncko M,
Hessler P, Lu X, Roberts-Rapp L, Pappano WN, Elmore SW, Souers AJ,
et al: MCL-1 is a key determinant of breast cancer cell survival:
Validation of MCL-1 dependency utilizing a highly selective small
molecule inhibitor. Mol Cancer Ther. 14:1837–1847. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bogenberger JM, Kornblau SM, Pierceall WE,
Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary
A, et al: BCL-2 family proteins as 5-Azacytidine-sensitizing
targets and determinants of response in myeloid malignancies.
Leukemia. 28:1657–1665. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Williams MM, Lee L, Hicks DJ, Joly MM,
Elion D, Rahman B, McKernan C, Sanchez V, Balko JM, Stricker T, et
al: Key survival factor, Mcl-1, correlates with sensitivity to
combined Bcl-2/Bcl-xL blockade. Mol Cancer Res. 15:259–268. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin KH, Winter PS, Xie A, Roth C, Martz
CA, Stein EM, Anderson GR, Tingley JP and Wood KC: Targeting
MCL-1/BCL-XL forestalls the acquisition of resistance to ABT-199 in
acute myeloid leukemia. Sci Rep. 6:276962016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luedtke DA, Niu X, Pan Y, Zhao J, Liu S,
Edwards H, Chen K, Lin H, Taub JW and Ge Y: Inhibition of Mcl-1
enhances cell death induced by the Bcl-2-selective inhibitor
ABT-199 in acute myeloid leukemia cells. Signal Transduct Target
Ther. 2:170122017. View Article : Google Scholar : PubMed/NCBI
|
